Cefditoren: Uses, Dosage, Side Effects and More

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Indonesia prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Pharyngitis, Tonsillitis, Uncomplicated skin and skin structure infections

Adult: As tab: 200 mg bid for 10 days. Dosage and treatment recommendations may vary between countries (refer to detailed local guidelines).
Child: ≥12 years As 200 mg tab: Same as adult dose.

Oral
Acute bacterial exacerbation of chronic bronchitis

Adult: As tab: 400 mg bid. Dosage and treatment recommendations may vary between countries (refer to detailed local guidelines).
Child: ≥12 years As 200 mg tab: Same as adult dose.

Oral
Community-acquired pneumonia

Adult: As tab: 200 mg bid (for mild cases) or 400 mg bid (for moderate cases). Treatment duration: 14 days. Dosage and treatment recommendations may vary between countries (refer to detailed local guidelines).
Child: ≥12 years As 200 mg tab: Same as adult dose.

Oral
Susceptible infections

Adult: As tab: 100-200 mg tid depending on the patient's age and severity of symptoms. Dosage and treatment recommendations and available dosage forms may vary between countries (refer to detailed local guidelines).
Child: As fine granules for oral solution: 9-18 mg/kg daily divided into 2-3 doses; adjust the daily dose depending on the patient's age and severity of symptoms. Dosage and treatment recommendations and available dosage forms may vary between countries (refer to detailed local guidelines).

What are the brands available for Cefditoren in Indonesia?

Renal Impairment

CrCl (mL/min)	Dosage
<30	Max: 200 mg once daily.
30-49	Max: 200 mg bid.

Administration

Should be taken with food.

Contraindications

Hypersensitivity to cefditoren or other cephalosporins. Carnitine deficiency; inborn errors of metabolism that may lead to clinically significant carnitine deficiency.

Special Precautions

Patient with history of penicillin allergy or gastrointestinal disease (particularly colitis); history of seizure disorders. Patients at risk for decreased prothrombin activity (e.g. poor nutritional state, long-term antimicrobial therapy, patients previously stabilised on anticoagulant treatment). Not recommended for long-term therapy because of the possibility of carnitine deficiency development. Renal and hepatic impairment. Children. Pregnancy and lactation.

Adverse Reactions

Significant: Increased INR (particularly during prolonged use or patients with poor nutritional state); manifestations of carnitine deficiency (long-term treatment); may increase the risk of seizures; fungal or bacterial superinfection (prolonged use).
Gastrointestinal disorders: Diarrhoea, nausea, abdominal pain, vomiting, dyspepsia.
Investigations: Abnormal LFTs, increased BUN.
Nervous system disorders: Headache.
Reproductive system and breast disorders: Vulvovaginal candidiasis.
Skin and subcutaneous tissue disorders: Rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Potentially Fatal: Serious hypersensitivity reactions; Clostridioides difficile-associated diarrhoea, pseudomembranous colitis.

Pregnancy Category (US FDA)

PO: B

Monitoring Parameters

Perform culture and susceptibility tests; consult local institutional recommendations before treatment initiation due to antibiotic resistance risks. Monitor renal function. Assess for signs and symptoms of anaphylaxis (during the initial dose) and pseudomembranous colitis.

Drug Interactions

Reduced absorption with antacids (e.g. Mg hydroxide, Al hydroxide) and histamine H₂-receptor antagonists (e.g. famotidine). Increased plasma concentration with probenecid.

Food Interaction

Increased bioavailability and maximum plasma concentration with high-fat meals.

Lab Interference

May result in positive direct Coombs' tests. May cause a false-positive reaction when testing for glucose in the urine using copper reduction tests (e.g. Benedict's or Fehling's solutions, Clinitest^®). May cause a false-negative result with ferricyanide test.

Action

Description:
Mechanism of Action: Cefditoren, a 3rd generation cephalosporin, binds to 1 or more of the penicillin-binding proteins (PBPs) causing the inhibition of bacterial cell wall synthesis, thereby resulting in bacterial cell lysis and death.
Pharmacokinetics:
Absorption: Absorbed from the gastrointestinal tract (cefditoren pivoxil). Increased bioavailability with high-fat meals. Bioavailability: Approx 15-20%. Time to peak plasma concentration: 1.5-3 hours.
Distribution: Plasma protein binding: 88%.
Metabolism: Cefditoren pivoxil is hydrolysed by esterases to form cefditoren (active metabolite) and pivalate; cefditoren is not appreciably metabolised.
Excretion: Mainly via urine (as unchanged drug). Elimination half-life: 1.5 hours.

Chemical Structure

Storage

Store below 30°C. Protect the fine granules for oral solution from light and moisture.

MIMS Class

Cephalosporins

ATC Classification

J01DD16 - cefditoren ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.

References

Brayfield A, Cadart C (eds). Cefditoren Pivoxil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 09/07/2024.

Cefditoren. UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 09/07/2024.

Meiact (Meiji). MIMS Thailand. http://www.mims.com/thailand. Accessed 09/07/2024.

Meiact 200 mg Film-coated Tablets (Meiji). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 09/07/2024.

Disclaimer: This information is independently developed by MIMS based on Cefditoren from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com